Neurogastrx develops investigational therapies for serious gastrointestinal (GI) disorders, including fexuprazan for erosive esophagitis (EE) and NG101 for gastroparesis. Fexuprazan is a novel potassium-competitive acid blocker (P-CAB) designed to more rapidly and durably suppress gastric acid than current proton pump inhibitors, and the company intends to initiate U.S. Phase 3 development in 2022. NG101, a dopamine D2 receptor antagonist, is in Phase 2 development in the U.S. The company notes large unmet need: EE affects 20% of the estimated 65 million U.S. GERD patients, and gastroparesis may affect as many as 10 million Americans. Neurogastrx announced a partnership with Daewoong Pharmaceuticals for development of fexuprazan in North America and is expanding its management team as it prepares for a pivotal growth phase. Proceeds from its recent financing will be used to advance the pipeline toward late‑stage development and potential commercialization. Neurogastrx is a Boston, MA-based private biopharmaceutical company focused on discovering and developing therapies for gastrointestinal disorders affecting the enteric nervous system. The company's lead asset, NG-101, is intended to treat gastroparesis. Neurogastrx raised $45M in a Series A financing to advance its programs. The company intends to use the funds to fill out the management team and reach proof of concept with NG-101. Leadership includes Jim O’Mara as President and Chief Executive Officer and Cyril De Colle as Founder and Chief Scientific Officer. In conjunction with the financing, Klaus Veitinger will become Chairman of the Board and David Allison, Aaron Royston and Kevin Koch will join the board of directors.

Total raised

$105M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2021